NeuroVive Pharmaceutical (OTCMKTS:NEVPF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Thursday.

According to Zacks, “NeuroVive Pharmaceutical AB is engaged in the research, discovery and development of mitochondrial-protecting pharmaceuticals. The company’s drug candidate consists of CicloMulsion(R) and NeuroSTAT(R) in clinical phases. CicloMulsion(R) is being studied for preoperative treatment of acute kidney injury coincident with major surgery and NeuroSTAT(R) is being studied for treating traumatic brain injury. NeuroVive Pharmaceutical AB is headquartered in Lund, Sweden. “

NEVPF opened at $0.32 on Thursday. NeuroVive Pharmaceutical has a 52 week low of $0.25 and a 52 week high of $0.67. The firm has a market cap of $16.22 million, a price-to-earnings ratio of -1.97 and a beta of 1.84.

NeuroVive Pharmaceutical Company Profile

NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. Its product portfolio includes NeuroSTAT, a drug candidate that is in Phase II clinical study for the treatment of traumatic brain injuries; and ToxPhos for the mitochondrial toxicity test.

See Also: What is the NASDAQ?

Get a free copy of the Zacks research report on NeuroVive Pharmaceutical (NEVPF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for NeuroVive Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroVive Pharmaceutical and related companies with's FREE daily email newsletter.